E. Rolland Dickson

E. Rolland Dickson's AcademicInfluence.com Rankings

E. Rolland Dickson

Mathematics

#7321

World Rank

#9971

Historical Rank

Statistics

#825

World Rank

#915

Historical Rank

mathematics Degrees

E. Rolland Dickson

Philosophy

#9197

World Rank

#12719

Historical Rank

Logic

#6186

World Rank

#7675

Historical Rank

philosophy Degrees

Download Badge

Mathematics
Philosophy

E. Rolland Dickson's Degrees

PhD Biostatistics University of California, Berkeley
Doctorate Medicine University of California, San Francisco

Why Is E. Rolland Dickson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

E. Rolland Dickson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A model to predict survival in patients with end‐stage liver disease (2001) (2667)
A model to predict survival in patients with end-stage liver disease. (2001) (1889)
Prognosis in primary biliary cirrhosis: Model for decision making (1989) (798)
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. (1997) (597)
Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis (1989) (588)
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) (1978) (494)
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. (1994) (438)
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. (2003) (407)
A revised natural history model for primary sclerosing cholangitis. (1997) (349)
Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis (1991) (299)
Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. (1993) (288)
Epidemiology and natural history of primary biliary cirrhosis in a U.S. community (2000) (286)
Primary sclerosing cholangitis: refinement and validation of survival models. (1992) (248)
Autoimmune associations in primary biliary cirrhosis. (1982) (248)
Bone loss and reduced osteoblast function in primary biliary cirrhosis. (1985) (226)
Primary biliary cirrhosis: Prediction of short‐term survival based on repeated patient visits (1994) (221)
Efficacy of liver transplantation in patients with primary biliary cirrhosis. (1989) (221)
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. (1996) (216)
Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two-dimensional contrast-enhanced echocardiography. (1990) (214)
Epidemiology and natural history of primary biliary cirrhosis in a US community. (2000) (196)
A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. (1990) (195)
Quality of life before and after liver transplantation for cholestatic liver disease (1999) (193)
Bone disease in liver transplant recipients: incidence, timing, and risk factors. (1991) (187)
Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. (1985) (183)
Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. (1989) (182)
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (2000) (181)
Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. (1995) (179)
Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. (1999) (179)
Time course of histological progression in primary biliary cirrhosis (1996) (175)
Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. (2001) (161)
Outcome of liver transplantation for hepatitis B in the United States (2004) (157)
Recurrence of nonalcoholic steatohepatitis following liver transplantation. (1996) (157)
Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end‐stage liver disease (2000) (157)
Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies (1996) (157)
Diagnosis of Wilson's disease presenting as fulminant hepatic failure. (1983) (156)
Trial of penicillamine in advanced primary biliary cirrhosis. (1985) (154)
Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. (1997) (152)
Deaths on the liver transplant waiting list: An analysis of competing risks (2006) (152)
Cost-Effectiveness of 6 and 12 Months of Interferon- Therapy for Chronic Hepatitis C (1997) (150)
SYSTEMIC AND RENAL HEMODYNAMIC DIFFERENCES BETWEEN FK506 AND CYCLOSPORINE IN LIVER TRANSPLANT RECIPIENTS (1993) (147)
Antimitochondrial antibody-negative primary biliary cirrhosis. (1995) (145)
Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis (1992) (142)
Cost‐effectiveness of ultrasound‐guided liver biopsy (1998) (141)
Splenosis: autotransplantation of splenic tissue. (1976) (141)
Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: What is the risk? (1992) (140)
Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. (1994) (136)
Primary biliary cirrhosis: Associations with class II major histocompatibility complex antigens (1987) (136)
Epitope mapping and reactivity of autoantibodies to the E2 component of 2‐oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2‐oxoglutarate dehydrogenase complex (1996) (136)
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis (1999) (133)
IMPACT OF NUTRITIONAL STATUS ON OUTCOMES AFTER LIVER TRANSPLANTATION1 (2000) (132)
Increased prevalence of antimitochondrial antibodies in first‐degree relatives of patients with primary biliary cirrhosis (2007) (128)
Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. (1999) (127)
Tumor necrosis factor‐α and transforming growth factor‐β reflect severity of liver damage in primary biliary cirrhosis (2002) (125)
The relative role of the child‐pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis (1999) (125)
Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. (1990) (123)
Pigmented corneal rings in non-Wilsonian liver disease. (1977) (120)
Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross‐reactive epitope(s) on protein X and dihydrolipoamide acetyltransferase of pyruvate dehydrogenase complex (1989) (118)
Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference? (1995) (118)
Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. (1993) (116)
Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. (1995) (111)
Predicting Survival among Patients Listed for Liver Transplantation: An Assessment of Serial MELD Measurements (2004) (111)
Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. (2008) (110)
Primary Sclerosing Cholangitis (1984) (110)
Extramural cross‐validation of the mayo primary biliary cirrhosis survival model establishes its generalizability (1989) (106)
Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA clone of branched‐chain α‐keto acid dehydrogenase dihydrolipoamide acyltransferase, the 52 kD mitochondrial autoantigen (1989) (106)
Outcome of hospital care of liver disease associated with hepatitis C in the United States (2001) (104)
Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. (1993) (103)
Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. (1998) (102)
The metabolic bone disease of primary sclerosing cholangitis (1991) (102)
Copper and primary biliary cirrhosis. (1974) (101)
Incidence of cancer in primary biliary cirrhosis: The mayo experience (1998) (99)
A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease (1997) (97)
The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. (1995) (94)
Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation (1997) (93)
Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. (1987) (90)
Optimal timing of liver transplantation for primary biliary cirrhosis (1998) (89)
Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: Relationship of levels of autoantibodies to disease progression (1997) (87)
Antimitochondrial antibodies of primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha-ketoacid dehydrogenase complex. (1989) (87)
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. (1999) (86)
Primary thrombocythaemia treated with busulphan (1986) (85)
Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. (1993) (81)
Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. (2002) (81)
Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. (2000) (81)
Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. (1995) (80)
Primary biliary cirrhosis and lichen planus. (1983) (80)
Changing Concepts in the Surgical Treatment of Gallstone Ileus: A Review of 15 Cases with Emphasis on Diagnosis and Treatment (1968) (78)
The economic impact of cytomegalovirus infection after liver transplantation. (2000) (74)
Lichen planus-like lesions caused by penicillamine in primary biliary cirrhosis. (1981) (73)
Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. (1997) (73)
Cirrhosis and death after jejunoileal shunt. (1972) (71)
Hepatic retransplantation in cholestatic liver disease: Impact of the interval to retransplantation on survival and resource utilization (1999) (71)
Effect of D-penicillamine on copper retention in patients with primary billiary cirrhosis. (1977) (70)
M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: Epitopes or epiphenomena? (1992) (66)
Asymptomatic primary biliary cirrhosis. Presentation, histology, and results with D-penicillamine. (1978) (65)
Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation. (1992) (65)
Lymphocyte cytotoxicity and inhibition studied with autologous liver cells: observations in chronic active liver disease and the primary biliary cirrhosis syndrome. (1976) (65)
Inhibition of α‐ketoglutarate dehydrogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis (1990) (65)
An association between HLA DR1 and lichen planus (1986) (64)
A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. (2001) (64)
TREATMENT OF PRURITUS OF CHOLESTASIS BY PLASMA PERFUSION THROUGH USP-CHARCOAL-COATED GLASS BEADS (1980) (63)
Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis (1986) (63)
Systemic giant-cell arteritis with polymyalgia rheumatica, reversible abnormalities of liver function. (1973) (63)
Pathogenesis of steatorrhea in primary biliary cirrhosis (1985) (61)
Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis (1988) (56)
Primary biliary cirrhosis. (1979) (51)
Adaptation of the mayo primary biliary cirrhosis natural history model for application in liver transplant candidates (2000) (49)
Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. (1994) (48)
Preciitating antibodies to mitochondrial antigens in patients with primary biliary cirrhosis. (1980) (47)
Nutritional status of a group of alcoholics before and after admission to an alcoholism treatment unit. (1981) (45)
ANTINUCLEAR ANTIBODIES IN PRIMARY BILIARY CIRRHOSIS (1984) (44)
Circulating IgG complexes in primary biliary cirrhosis. A serial study in forty patients followed for two years. (1978) (44)
Studies of chronic idiopathic jaundice (Dubin-Johnson syndrome). II. Evaluation of a large family with the trait. (1963) (43)
A prospective study of pulmonary function and gas exchange following liver transplantation. (1992) (41)
Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. (1993) (41)
Employment and Health Insurance in Long‐Term Liver Transplant Recipients (2005) (40)
Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis (1998) (39)
Abnormal expression of PDC‐E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody‐negative primary biliary cirrhosis (1995) (39)
Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis (1995) (38)
Primary sclerosing cholangitis. (1984) (38)
Systemic and Renal Effects of Nifedipine in Cyclosporine‐Associated Hypertension (1994) (37)
Results of long-term ursodiol treatment for patients with primary biliary cirrhosis (2002) (36)
Plasmaperfusion for the treatment of intractable pruritus of cholestasis. (1978) (35)
Enzyme inhibitory autoantibodies to pyruvate dehydrogenase complex in primary biliary cirrhosis: Applications of a semiautomated assay (1994) (33)
Lichen planus, primary biliary cirrhosis and penicillamine (1982) (33)
Combined analysis of French, American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis (1995) (32)
Preoperative predictors of resource utilization in liver transplantation. (1995) (30)
Application of the Mayo primary biliary cirrhosis survival model to Mayo liver transplant patients. (1989) (30)
Human liver and conjugation of catecholamines. (1987) (30)
The pharmacokinetics of D-penicillamine in man. (1981) (28)
The association of Churg-Strauss vasculitis with temporal artery involvement, primary biliary cirrhosis, and polychondritis in a single patient. (1982) (26)
Pigmented corneal rings in a patient with primary biliary cirrhosis. (1975) (25)
Hepatic subcellular distribution of copper in primary biliary cirrhosis. Comparison with other hyperhepatocupric states and review of the literature. (1977) (25)
Adjuvant Cholylsarcosine During Ursodeoxycholic Acid Treatment of Primary Biliary Cirrhosis (1998) (25)
Comparative immunoreactive profiles of Japanese and American patients with primary biliary cirrhosis against mitochondrial autoantigens. (1992) (24)
The natural history of abdominal pain associated with primary biliary cirrhosis. (1994) (24)
Removal of bile acids and bilirubin by plasmaperfusion of U.S.P. charcoal-coated glass beads. (1979) (24)
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. (1999) (23)
Copper stains and the syndrome of primary biliary cirrhosis. Evaluation of staining methods and their usefulness for diagnosis and trials of penicillamine treatment. (1979) (22)
Liver transplantation for primary sclerosing cholangitis: impact of risk factors on outcome. (1996) (21)
Primary biliary cirrhosis: Relation between hepatic function and pulmonary function in patients who never smoked (1991) (21)
Inhibition of alpha-ketoglutarate dehydrogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis. (1990) (19)
Alpha1-antitrypsin phenotypes in chronic active liver disease and primary biliary cirrhosis. (1976) (18)
Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy (1998) (18)
Cholangiographic findings in cholangiolitic hepatitis. Syndrome of primary biliary cirrhosis. (1971) (17)
Glucose-6-phosphate dehydrogenase variants: reexamination of G6PD Chicago and Cornell and a new variant (G6PD Pea Ridge) resembling G6PD Chicago. (1980) (17)
Chronic active hepatitis : the Mayo Clinic experience (1986) (17)
Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy. (1998) (15)
Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload. (1978) (15)
Is primary sclerosing cholangitis a progressive disease or not? (1988) (15)
The autologous mixed lymphocyte reaction in primary biliary cirrhosis: Analysis of activation and blastogenesis of autoreactive T lymphocytes (1988) (15)
Hepatoportal arteriovenous fistula: morphologic features studied after orthotopic liver transplantation. (1989) (15)
d-Penicillamine in primary biliary cirrhosis: apparent beneficial effects in spite of a lack of correlation with changes in hepatic copper concentrations (1978) (14)
The relative affinity of recombinant dihydrolipoamide transacetylase for autoantibodies in primary biliary cirrhosis (1990) (12)
Conversion from standard cyclosporine to low-dose cyclosporine and azathioprine therapy as treatment for cyclosporine-related complications in liver transplant patients. (1987) (12)
Primary biliary cirrhosis: Dutch application of the Mayo Model before and after orthotopic liver transplantation. (1997) (11)
D-penicillamine improves survival and retards histologic progression in primary biliary cirrhosis (1982) (10)
Prediction of liver transplant outcome using the MELD scale (2001) (10)
Rupture of abdominal aortic aneurysm into vena cava. Electrocardiographic changes. (1963) (9)
Immune complexes in primary biliary cirrhosis. Higher prevalence of circulating immune complexes in patients with associated autoimmune features. (1982) (9)
ULTRASTRUCTURAL CHANGES OF THE LIVER IN BENIGN RECURRENT CHOLESTASIS. (1965) (9)
Plasmaperfusion and studies of copper metabolism in benign recurrent cholestasis: novel procedures in a rare syndrome. (1980) (8)
Primary biliary cirrhosis clinical research single‐topic conference (1996) (8)
Pharmacokinetics of D-penicillamine in normals and primary biliary cirrhosis (PBC) (1979) (7)
Predictive models of natural history in primary biliary cirrhosis. (1998) (7)
Lichen planus and the liver (1991) (6)
Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy (1995) (6)
759 Outcome of liver transplantation for hepatitis B in the U.S. (2003) (6)
The composition of the isolated soluble immune complexes in primary biliary cirrhosis (PBC) (1978) (5)
Economic analysis of interferon/ribavirin treatment in patients with chronic hepatitis C who relapse following initial interferon therapy (1998) (5)
The timing of liver transplantation in primary biliary cirrhosis. (2000) (5)
Comparative metabolism and structure of BCKD-E2 in primary biliary cirrhosis. (1993) (5)
Hereditary sideroblastic anemia. (1991) (4)
Timing of liver transplantation. (2000) (4)
Chronic active liver disease with common variable hypogammaglobulinemia. (1979) (4)
25 – NUTRITIONAL STATUS OF ALCOHOLICS BEFORE AND AFTER ADMISSION TO AN ALCOHOLISM TREATMENT UNIT (1979) (4)
The role of prognostic models in the timing of liver transplantation. Application in cholestatic liver diseases. (1997) (3)
The Mayo risk score increases rapidly in the terminal phase of primary sclerosing cholangitis (1998) (3)
Survival algorithms and outcome analysis in primary biliary cirrhosis. (1997) (3)
Antemortem diagnosis and short-term survival of a patient with Wilson's disease presenting as fulminant hepatic failure (1984) (3)
Methotrexate in the treatment of primary biliary cirrhosis: the hype and the hope. (1999) (3)
Depletion of Bile Acids and Bilirubin in Dogs with Biliary Obstruction by Plasmaperfusion of Usp-Charcoal-Coated Glass Beads (1980) (3)
Liver transplantation for primary biliary cirrhosis (1992) (2)
Is routine cholangiography useful in men with suspected primary biliary cirrhosis? (1999) (2)
Gallium accumulation in the stomach: a false-positive scan suggesting abscess. (1979) (2)
The syndrome of primary biliary cirrhosis. (1981) (2)
Intrahepatic Distribution of Tritiated Bilirubin in Normal and Gunn Rats (1967) (2)
Prognosis in PBC: Who should we believe? (1990) (1)
Hormone replacement therapy is safe and effective in decreasing bone loss in postmenopausal patients with primary biliary cirrhosis (2000) (1)
Tune course of histological progression in primary biliary cirrhosis (1996) (1)
Long-term ursodeoxycholic acid therapy delays histologic progression in primary biliary cirrhosis (1998) (1)
Reply (2001) (0)
Prevalence of celiac disease in a north american population with primary biliary cirrhosis - is screening worthwhile? (2000) (0)
Sa1027 Plasma Cysteine Levels and Muscle Cramps in Patients With Cirrhosis (2012) (0)
The pharmacokinetics of D-penicillamine in health and primary biliary cirrhosis (PBC) (1980) (0)
Natural history models of primary biliary cirrhosis (1998) (0)
Cholestatic liver disease: an overview. (1998) (0)
Letter: Polymyalgia rheumatica and liver disease. (1974) (0)
540 Estimation of glomerular filtration rate in patients with end-stage liver disease: a new model superior to Cockroft-Gault (2003) (0)
Hepatopulmonary Syndrome* ClinicalObservations andLackof Therapeutic ResponseToSomatostatin Analogue (2017) (0)
12 PROGNOSTIC VALUE OF SERUM SODIUM CONCENTRATION AND MODEL FOR END-STAGE LIVER DISEASE IN PATIENTS ON THE LIVER TRANSPLANTATION WAITING LIST (2005) (0)
ADAPTATION OF THE MAYO PRIMARY BILIARY CIRRHOSIS MODEL FOR MINIMUM LISTING CRITERIA FOR LIVER TRANSPLANT CANDIDATES (1998) (0)
Mortality and expenditure related to hepatitis C in the US (2000) (0)
intheImpairment ofOsteoblast Proliferation Associated withCholestatic Jaundice (1995) (0)
Reply of the authors: Determination of Copper in Needle Biopsies of the Liver (1975) (0)
LOWER QUALITY OF LIFE IN LIVER TRANSPLANT RECIPIENTS WITH HEPATITIS C.: Abstract# 398 Poster Board #‐Session: P38‐II (2000) (0)
DETERMINANTS OF OUTCOME OF LIVER TRANSPLANTATION IN US, 1988‐1996.: Abstract# 987 (2000) (0)
Silymarin for patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (2000) (0)
POLYMYALGIA RHEUMATICA AND LIVER DISEASE (1974) (0)
The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study (1995) (0)
Short-term ursodeoxycholic acid therapy delays stage progression in patients with primary biliary cirrhosis (2000) (0)
Asymptomatic primary biliary cirrhosis: Presentation, histology, and short-term course in d-penicillamine trial (1978) (0)
Characterisation ofpatients withacomplete biochemical responsetoursodeoxycholic acid (2011) (0)
Nutritional assessment parameters in patients awaiting liver transplantation: Correlation with body cell mass (1998) (0)
Alpha1 low density lipoprotein: A marker for primary biliary cirrhosis (1978) (0)

This paper list is powered by the following services:

E. Rolland Dickson's Academic­Influence.com Rankings

E. Rolland Dickson's Degrees

Why Is E. Rolland Dickson Influential?

E. Rolland Dickson's Published Works

Published Works

E. Rolland Dickson's AcademicInfluence.com Rankings